English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Thrombin generation testing has been used to provide information on the coagulation phenotype of patients. The most used technique is the calibrated automated thrombogram ( CAT ) but it suffers from a lack of standardization, preventing its implementation in routine. The  ST  Genesia is a new analyzer designed to assess thrombin generation based on the same principle as the  CAT . Unlike the  CAT  system, the  ST  Genesia is a benchtop, fully automated analyzer, able to perform the analyses individually and not by batch, with strict control of variables such as temperature and volumes, ensuring, theoretically, maximal reproducibility.    Objectives  This study aimed at assessing the performance of the  STG ‐DrugScreen application on the  ST  Genesia analyzer. We also aimed at exploring stability of plasma samples after freezing and defining a reference normal range.    Results  Results demonstrated the excellent interexperiment precision of the  ST  Genesia and confirmed that the use of a reference plasma helps reducing the inter‐experiments variability. Stability revealed that plasma samples are stable for at least 11 months at −70°C or lower, except for those containing low molecular weight heparins which have to be tested within 6 months. Freezing had no effect on the majority of thrombin generation parameters except on time to peak.    Conclusions  Our results suggest an easy implementation of thrombin generation with the use of  ST  Genesia in the routine laboratory. This will facilitate the design of multicentric studies and enable the establishment of reliable and evidence‐based thresholds, which may improve the management of patients treated with anticoagulants.

Assessment of the analytical performances and sample stability on ST Genesia system using the STG ‐DrugScreen application